Source comparison
Oral vs Injectable BPC-157 — Bioavailability and Stability Gaps
BPC-157 is marketed in both oral capsules and injectable formulations, but telehealth clinicians researching BPC-157 should understand that these are not interchangeable delivery methods. The gastric stability claim that dominates marketing materials is based
This comparison does not assign a generated winner or score.
- BPC-157 is marketed in both oral capsules and injectable formulations, but telehealth clinicians researching BPC-157 should understand that these are not interchangeable delivery methods. The gastric stability claim that dominates marketing materials is based on one mechanistic property (resistance to pepsin degradation) that doesn't prove systemic bioavailability after oral administration. Peptides are chains of amino acids linked by peptide bonds, and the human digestive system is specifically designed to break those bonds into free amino acids for absorption. BPC-157's resistance to pepsin (the primary gastric protease) doesn't address trypsin, chymotrypsin, or the array of brush-border peptidases in the small intestine.
- The 2017 study most frequently cited to support oral bioavailability showed that BPC-157 retained biological activity when administered intragastrically to rats. But intragastric gavage bypasses the mouth, esophagus, and normal digestive mixing, delivering the peptide directly into the stomach in a bolus. That's not the same as swallowing a capsule, where the peptide is exposed to salivary amylase, esophageal transit time, and variable gastric pH depending on fed or fasted state. No published study has measured plasma BPC-157 concentrations after oral capsule administration in humans, which means telehealth clinicians researching BPC-157 are recommending oral dosing without pharmacokinetic evidence that the peptide reaches systemic circulation intact.
- Subcutaneous injection avoids first-pass metabolism entirely, delivering the peptide directly into interstitial fluid where it can diffuse into capillaries and lymphatic vessels. This is standard for peptides like semaglutide, insulin, and growth hormone. All of which would be inactive if taken orally. The typical subcutaneous dose used in experimental protocols is 250–500 mcg once or twice daily, injected near the injury site or into abdominal subcutaneous tissue. Telehealth clinicians researching BPC-157 should clarify with patients: oral formulations may have local gastroprotective effects (the original intended use), but systemic tissue repair effects almost certainly require injectable administration if the mechanism involves VEGF upregulation at distant injury sites.
- There's also a stability question. Lyophilized (freeze-dried) BPC-157 is stable at room temperature for months, but once reconstituted with bacteriostatic water, the peptide degrades within 2–4 weeks even under refrigeration at 2–8°C. This is standard for most research peptides, but telehealth clinicians researching BPC-157 need to communicate storage requirements clearly. Patients who reconstitute a vial and leave it at room temperature for a week are injecting degraded amino acid fragments, not an active peptide. Our team has reviewed dozens of patient protocols where improper storage likely explains the lack of response.